Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients


ABSTRACT: We evaluated blood samples from 6 patients with metastatic melanoma treated with anti-LAG3+anti-PD1 (160+480 mg) in a phase I trial (NCT01968109) using single-cell RNA and T cell receptor (TCR) sequencing (scRNA+TCRαβ-seq, 10X 5') combined with other multiomics profiling (flow, cytokine, TCRb-seq) from a larger cohort of 40 patients. This data set include three time points, including baseline, 1 month, and 3 month. The sorting is CD45+.

INSTRUMENT(S): Illumina NovaSeq 6000

ORGANISM(S): Homo sapiens

SUBMITTER: Jani Huuhtanen 

PROVIDER: E-MTAB-12733 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications


BackgroundRelatlimab plus nivolumab (anti-lymphocyte-activation gene 3 plus anti-programmed death 1 [anti-LAG-3+anti-PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on the immune system is unknown.MethodsWe evaluated blood samples from 40 immunotherapy-naive or prior immunotherapy-refractory patients with metastatic melanoma treated with anti-LAG-3+anti-PD-1 in a phase I trial using single-cell RNA and T cell receptor sequencing (scR  ...[more]

Similar Datasets

2018-08-08 | E-MTAB-6660 | biostudies-arrayexpress
2023-08-18 | PXD027525 | Pride
2014-02-01 | E-MTAB-1798 | biostudies-arrayexpress
2014-02-01 | E-MTAB-1808 | biostudies-arrayexpress
2014-10-06 | E-GEOD-62080 | biostudies-arrayexpress
2022-10-13 | PXD033989 | Pride
2011-11-05 | E-GEOD-33469 | biostudies-arrayexpress
2016-01-19 | E-GEOD-72951 | biostudies-arrayexpress
2021-07-30 | PXD023849 | Pride
2013-08-02 | E-GEOD-42328 | biostudies-arrayexpress